Details for Patent: 7,785,627

« Back to Dashboard

Which drugs does patent 7,785,627 protect, and when does it expire?

Patent 7,785,627 protects ACTOPLUS MET XR and is included in one NDA.

This patent has seventy-two patent family members in twenty-five countries.

Summary for Patent: 7,785,627

Title:	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Abstract:	A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
Inventor(s):	Unchalee Kositprapa, Robert I. Goldfarb, John Cardinal, Avinash Nangia
Assignee:	Actavis Holdco US Inc
Application Number:	US10/664,803
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,785,627
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 7,785,627

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No			Y

International Family Members for US Patent 7,785,627

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	054238
Australia	2003272504
Australia	2004283059